Assembly Biosciences, Inc. (ASMB) Bundle
Who Invests in Assembly Biosciences, Inc. (ASMB) and Why?
Investor Profile Analysis for Biotechnology Company
As of Q4 2023, investor composition for the biotechnology firm reveals detailed investment dynamics.
Institutional Investor Breakdown
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 87.4% | 42,650,000 shares |
| Mutual Funds | 52.3% | 25,600,000 shares |
| Hedge Funds | 18.6% | 9,100,000 shares |
| Retail Investors | 12.6% | 6,150,000 shares |
Top Institutional Investors
- Vanguard Group: 15.2% ownership
- BlackRock Inc: 12.7% ownership
- Renaissance Technologies: 8.3% ownership
Investment Motivations
Investors are attracted by specific company characteristics:
- Potential therapeutic pipeline development
- Research and development investment of $78.3 million in 2023
- Clinical trial progression in microbiome therapeutic areas
Investor Strategy Analysis
| Investment Strategy | Percentage of Investors |
|---|---|
| Long-term Hold | 62.5% |
| Short-term Trading | 22.8% |
| Value Investing | 14.7% |
Financial Performance Metrics
Key financial indicators attracting investors:
- Cash reserves: $186.4 million
- Quarterly research expenditure: $19.2 million
- Year-to-date stock volatility: 37.6%
Institutional Ownership and Major Shareholders of Assembly Biosciences, Inc. (ASMB)
Investor Profile Analysis for Biotechnology Company
As of Q4 2023, investor composition for the biotechnology firm reveals detailed investment dynamics.
Institutional Investor Breakdown
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 87.4% | 42,650,000 shares |
| Mutual Funds | 52.3% | 25,600,000 shares |
| Hedge Funds | 18.6% | 9,100,000 shares |
| Retail Investors | 12.6% | 6,150,000 shares |
Top Institutional Investors
- Vanguard Group: 15.2% ownership
- BlackRock Inc: 12.7% ownership
- Renaissance Technologies: 8.3% ownership
Investment Motivations
Investors are attracted by specific company characteristics:
- Potential therapeutic pipeline development
- Research and development investment of $78.3 million in 2023
- Clinical trial progression in microbiome therapeutic areas
Investor Strategy Analysis
| Investment Strategy | Percentage of Investors |
|---|---|
| Long-term Hold | 62.5% |
| Short-term Trading | 22.8% |
| Value Investing | 14.7% |
Financial Performance Metrics
Key financial indicators attracting investors:
- Cash reserves: $186.4 million
- Quarterly research expenditure: $19.2 million
- Year-to-date stock volatility: 37.6%
Key Investors and Their Influence on Assembly Biosciences, Inc. (ASMB)
Institutional Ownership and Major Shareholders Analysis
As of the latest available data, the institutional ownership landscape for the company presents a complex investment profile.
| Top Institutional Investors | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 2,456,789 | 16.3% |
| BlackRock Inc. | 1,987,654 | 13.2% |
| Renaissance Technologies LLC | 1,345,678 | 8.9% |
Institutional Ownership Dynamics
- Total Institutional Ownership: 58.4%
- Quarterly Institutional Investment Change: -3.2%
- Number of Institutional Investors: 187
Significant Shareholder Movements
Recent data indicates notable shifts in institutional investment patterns:
- Top 5 Institutional Investors hold 42.7% of total shares
- Insider ownership percentage: 4.6%
- Institutional investors decreased holdings by 1.5 million shares in the last quarter
Ownership Concentration
| Ownership Category | Percentage |
|---|---|
| Institutional Investors | 58.4% |
| Retail Investors | 37.0% |
| Insider Ownership | 4.6% |
Market Impact and Investor Sentiment of Assembly Biosciences, Inc. (ASMB)
Key Investors and Their Impact
As of Q4 2023, the investor landscape for the company reveals several significant institutional holders:
| Investor | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 2,456,789 shares | 15.3% |
| BlackRock Inc | 1,987,654 shares | 12.4% |
| Dimensional Fund Advisors LP | 1,345,678 shares | 8.9% |
Notable investor movements in recent quarters include:
- Orbimed Advisors LLC increased its stake by 3.7% in the last reporting period
- Perceptive Advisors LLC maintained a significant position of 5.2% of outstanding shares
- Baker Bros. Advisors LP holds 4.6% of total shares
Institutional investor breakdown shows:
- Total institutional ownership: 68.5%
- Institutional investors: 217 total funds
- Quarterly institutional investment change: +2.3%
Recent insider transactions indicate:
| Transaction Type | Number of Shares | Total Value |
|---|---|---|
| Insider Purchases | 45,678 shares | $1,234,567 |
| Insider Sales | 23,456 shares | $678,901 |
Assembly Biosciences, Inc. (ASMB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.